The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors.
COVID-19
COVID-19 serotherapy
T cell
neutralizing antibodies
t-lymphocyte
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
11
2021
accepted:
27
01
2022
entrez:
4
4
2022
pubmed:
5
4
2022
medline:
6
4
2022
Statut:
epublish
Résumé
Convalescent plasma therapy has been described as an attractive approach to treat critically ill patients with COVID-19 (Coronavirus disease 2019). The selection of convalescent plasma donors (CPD) is commonly based on neutralizing antibody titer. A better understanding of the quality of immune responses following COVID-19 will enable the optimization of convalescent donors' selection in convalescent plasma programs. The involvement of SARS-CoV-2 specific T cells in the induction and persistence of high affinity anti-SARS-CoV-2 neutralizing antibody is still poorly investigated. In this study, 115 CPD who presented SARS-CoV-2 and who were eligible for plasma donation were included. Comprehensive analysis of T cells together with humoral responses were performed in regards of sex, age and blood group type. High frequency of T cell responses against SARS-CoV-2 related protein such as spike glycoprotein (80.0%), nucleocapsid (NCAP) (70.4%) and membrane protein (VME1) (74.8%) were detected in CPD by e
Identifiants
pubmed: 35372242
doi: 10.3389/fpubh.2022.816848
pmc: PMC8965758
doi:
Substances chimiques
Antibodies, Neutralizing
0
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
816848Informations de copyright
Copyright © 2022 Kroemer, Boullerot, Ramseyer, Spehner, Barisien, Gravelin, Renaudin, Cognasse, Gallian, Hermine, Lacombe, Tiberghien and Adotévi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Med (N Y). 2020 Dec 18;1(1):66-77
pubmed: 33363284
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6
pubmed: 15616839
JAMA. 2020 Dec 1;324(21):2151-2152
pubmed: 33175110
Nature. 2021 Sep;597(7875):268-273
pubmed: 34320609
JAMA. 2021 Feb 16;325(7):632-644
pubmed: 33475701
J Clin Invest. 2021 Feb 1;131(3):
pubmed: 33320842
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Clin Microbiol Infect. 2021 Jan;27(1):19-27
pubmed: 32860962
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Immunol Rev. 2006 Jun;211:236-54
pubmed: 16824132
N Engl J Med. 2007 Oct 4;357(14):1450-1
pubmed: 17914053
Trends Immunol. 2021 Jan;42(1):18-30
pubmed: 33277181
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
J Infect. 2021 Feb;82(2):282-327
pubmed: 32853599
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Nat Immunol. 2021 Jan;22(1):74-85
pubmed: 32999467
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
N Engl J Med. 2021 Mar 18;384(11):1015-1027
pubmed: 33523609
Blood. 2020 Nov 12;136(20):2290-2295
pubmed: 32959052
N Engl J Med. 2016 Jan 7;374(1):33-42
pubmed: 26735992
N Engl J Med. 2020 Dec 10;383(24):2333-2344
pubmed: 33085857
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
BMJ. 2020 Oct 22;371:m3939
pubmed: 33093056
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
J Exp Med. 2007 Jun 11;204(6):1405-16
pubmed: 17535971
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
N Engl J Med. 2021 Feb 18;384(7):619-629
pubmed: 33232588
Virol J. 2018 Dec 27;15(1):192
pubmed: 30587193
N Engl J Med. 2021 Feb 18;384(7):610-618
pubmed: 33406353